DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-6.23%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$4.75B
AUM Growth
+$4.75B
(-7.1%)
Cap. Flow
-$1.71M
Cap. Flow
% of AUM
-0.04%
Top 10 Holdings %
Top 10 Hldgs %
40.09%
Holding
155
New
21
Increased
16
Reduced
21
Closed
27
Top Buys
| 1 |
AdaptHealth
AHCO
|
$51.9M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$46.6M |
| 3 |
Xilio Therapeutics
XLO
|
$33.7M |
| 4 |
Viatris
VTRS
|
$26.4M |
| 5 |
Esperion Therapeutics
ESPR
|
$25M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$33.2M |
| 2 |
Molina Healthcare
MOH
|
$30.8M |
| 3 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
$28.5M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$25M |
| 5 |
Pacira BioSciences
PCRX
|
$22.3M |
Sector Composition
| 1 | Healthcare | 63.21% |
| 2 | Financials | 1.41% |
| 3 | Consumer Discretionary | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Xilio Therapeutics
XLO
$37.5M
| $33.7M | 0.71% |
+2,154,061
| New | +$33.7M |
|
|
AERI
27
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $33M | 0.69% |
4,695,020
+1,718,000
| +58% | +$12.1M |
|
28
The Oncology Institute
TOI
$302M
| $32.1M | 0.67% |
3,296,107
-1,703,893
| -34% | -$16.6M |
|
29
Nuvation Bio
NUVB
$1.08B
| $30.4M | 0.64% |
3,577,233
| – | – |
|
|
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
| $28M | 0.59% |
452,000
-58,673
| -11% | -$3.64M |
|
|
31
Esperion Therapeutics
ESPR
$490M
| $25M | 0.52% |
+5,000,000
| New | +$25M |
|
32
BioCryst Pharmaceuticals
BCRX
$1.74B
| $23.4M | 0.49% |
1,686,140
+1,451,497
| +619% | +$20.1M |
|
|
VIVO
33
DELISTED
Meridian Bioscience Inc
VIVO
| $23M | 0.48% |
1,125,083
-938,000
| -45% | -$19.1M |
|
34
FIGS
FIGS
$1.08B
| $22.9M | 0.48% |
+829,707
| New | +$22.9M |
|
35
Pharvaris
PHVS
$1.41B
| $22.8M | 0.48% |
1,581,331
-27,140
| -2% | -$391K |
|
36
Revolution Medicines
RVMD
$7.43B
| $22.4M | 0.47% |
891,587
-674,125
| -43% | -$17M |
|
37
Brookdale Senior Living
BKD
$1.81B
| $22.1M | 0.46% |
4,274,808
-977,992
| -19% | -$5.05M |
|
38
Alector
ALEC
$282M
| $21.8M | 0.46% |
1,055,192
| – | – |
|
|
BLU
39
DELISTED
BELLUS Health Inc.
BLU
| $19.7M | 0.41% |
+2,449,000
| New | +$19.7M |
|
|
PROF
40
Profound Medical
PROF
$131M
| $19.2M | 0.4% |
1,713,797
+416,000
| +32% | +$4.67M |
|
41
Rhythm Pharmaceuticals
RYTM
$6.75B
| $18.6M | 0.39% |
1,867,467
-122,158
| -6% | -$1.22M |
|
42
Outset Medical
OM
$245M
| $18.5M | 0.39% |
400,622
| – | – |
|
|
NVRO
43
DELISTED
NEVRO CORP.
NVRO
| $17.5M | 0.37% |
+216,000
| New | +$17.5M |
|
|
KNTE
44
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $17.5M | 0.37% |
985,568
-42,940
| -4% | -$761K |
|
|
ONCR
45
DELISTED
Oncorus, Inc.
ONCR
| $16.6M | 0.35% |
3,148,977
| – | – |
|
46
Terns Pharmaceuticals
TERN
$651M
| $16.6M | 0.35% |
2,345,959
| – | – |
|
47
Apellis Pharmaceuticals
APLS
$3.51B
| $16.2M | 0.34% |
+343,213
| New | +$16.2M |
|
|
INZY
48
DELISTED
Inozyme Pharma
INZY
| $16M | 0.34% |
2,344,786
| – | – |
|
|
DALS
49
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $15.7M | 0.33% |
1,600,000
| – | – |
|
50
KalVista Pharmaceuticals
KALV
$713M
| $15.5M | 0.33% |
1,175,131
-988,423
| -46% | -$13.1M |
|